Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction

JACC: Heart Failure

Volumn 6, Issue 1, 2018, Pages 1-7

  Paulus, Walter J ^a   Dal Canto, Elisa ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

diabetes mellitus; heart failure; myocardium

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; INSULIN; ORAL ANTIDIABETIC AGENT; TROPONIN T; ANTIDIABETIC AGENT;

CAPILLARY ENDOTHELIAL CELL; CARDIAC MUSCLE CELL; CELL DEATH; CELL SPECIFICITY; CORONARY FLOW RESERVE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GLYCEMIC CONTROL; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART MUSCLE COMPLIANCE; HEART MUSCLE INJURY; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERINSULINEMIA; LIPOTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; UPREGULATION; CARDIAC MUSCLE; COMORBIDITY; HEART FAILURE; HEART STROKE VOLUME; LOW CARBOHYDRATE DIET; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

COMORBIDITY; DIABETES MELLITUS; DIET, CARBOHYDRATE-RESTRICTED; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIUM; STROKE VOLUME;

EID: 85039972259     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2017.07.012     Document Type: Review

References (64)

1. Mentz, R.J., Kelly, J.P., von Lueder, T.G., et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 64 (2014), 2281–2293.
2. Ather, S., Chan, W., Bozkurt, B., et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 59 (2012), 998–1005.
3. MacDonald, M.R., Petrie, M.C., Varyani, F., et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29 (2008), 1377–1385.
4. Haass, M., Kitzman, D.W., Anand, I.S., et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction/clinical perspective. Circ Heart Fail 4 (2011), 324–331.
5. van Heerebeek, L., Hamdani, N., Handoko, M.L., et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117 (2008), 43–51.
6. Paulus, W.J., Tschoepe, C., A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62 (2013), 263–271.
7. Redfield, M.M., Heart Failure with Preserved Ejection Fraction. N Engl J Med 375 (2016), 1868–1877.
8. Santhanakrishnan, R., Chong, J.P., Ng, T.P., et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 14 (2012), 1338–1347.
9. Sanders-van Wijk, S., van Empel, V., Davarzani, N., et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail 17 (2015), 1006–1014.
10. Franssen, C., Chen, S., Unger, A., et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. J Am Coll Cardiol HF 4 (2016), 312–324.
11. Orasanu, G., Plutzky, J., The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 53:Suppl 5 (2009), S35–S42.
12. Mohammed, S.F., Hussain, S., Mirzayev, S.A., Edwards, W.D., Maleszewski, J.J., Redfield, M.M., Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 131 (2015), 550–559.
13. Srivaratharajah, K., Coutinho, T., deKemp, R., et al. Reduced myocardial flow in heart failure patients with preserved ejection fraction. Circ Heart Fail, 9, 2016, e002562.
14. Borlaug, B.A., Olson, T.P., Lam, C.S., et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 56 (2010), 845–854.
15. Akiyama, E., Sugiyama, S., Matsuzawa, Y., et al. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 60 (2012), 1778–1786.
16. Khavandi, K., Aghamohammadzadeh, R., Luckie, M., et al. Abnormal remodeling of subcutaneous small arteries is associated with early diastolic impairment in metabolic syndrome. J Am Heart Assoc, 6, 2017, 4.
17. Westermann, D., Lindner, D., Kasner, M., et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 4 (2011), 44–52.
18. Heymes, C., Bendall, J.K., Ratajczak, P., et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41 (2003), 2164–2171.
19. Zamani, P., French, B., Brandimarto, J.A., et al. Effect of heart failure with preserved ejection fraction on nitric oxide metabolites. Am J Cardiol 118 (2016), 1855–1860.
20. Chirinos, J.A., Akers, S.R., Trieu, L., et al. Heart failure, left ventricular remodeling, and circulating nitric oxide metabolites. J Am Heart Assoc, 5, 2016, e004133.
21. Van Heerebeek, L., Hamdani, N., Falcão-Pires, I., et al. Low myocardial protein kinase g activity in heart failure with preserved ejection fraction. Circulation 126 (2012), 830–839.
22. Asburn, J., Villareal, F.J., The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 47 (2006), 693–700.
23. Bayeva, M., Sawicki, K.T., Ardehali, H., Taking diabetes to heart: deregulation of myocardial lipid metabolism in diabetic cardiomyopathy. J Am Heart Assoc, 2, 2013, e000433.
24. Randle, P.J., Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14 (1998), 263–283.
25. Desvergne, B., Michalik, L., Wahli, W., Transcriptional regulation of metabolism. Physiol Rev 86 (2006), 465–514.
26. Lopaschuk, G.D., Ussher, J.R., Folmes, C.D., Jaswal, J.S., Stanley, W.C., Myocardial fatty acid metabolism in health and disease. Physiol Rev 90 (2010), 207–258.
27. Witteles, R.M., Fowler, M.B., Insulin-resistant cardiomyopathy: clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 51 (2008), 93–102.
28. Boudina, S., Abel, E.D., Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology 21 (2006), 250–258.
29. Diamant, M., Lamb, H.J., Groeneveld, Y., et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 42 (2003), 328–335.
30. Zieman, S.J., Melenovsky, V., Clattenburg, L., et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 25 (2007), 577–583.
31. Donaldson, C., Taatjes, D.J., Zile, M., et al. Combined immunoelectron microscopic and computer–assisted image analyses to detect advanced glycation end-products in human myocardium. Histochem Cell Biol 134 (2010), 23–30.
32. Zhang, M., Kho, A.L., Anilkumar, N., et al. Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase. Circulation 113 (2006), 1235–1243.
33. Liu, Y., Yu, M., Zhang, Z., et al. Blockade of receptor for advanced glycation end products protects against systolic overload-induced heart failure after transverse aortic constriction in mice. Eur J Pharmacol 791 (2016), 535–543.
34. Maier, H.J., Schips, T.G., Wietelmann, A., et al. Cardiomyocyte-specific IκB kinase (IKK)/NF-κB activation induces reversible inflammatory cardiomyopathy and heart failure. Proc Natl Acad Sci U S A 109 (2012), 11794–11799.
35. Seferović P.M., Paulus, W.J., Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 36 (2015), 1718–1727.
36. Bertoni, A.G., Tsai, A., Kasper, E.K., Brancati, F.L., Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care 26 (2003), 2791–2795.
37. MacDonald, M.R., Petrie, M.C., Hawkins, N.M., Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 29 (2008), 1224–1240.
38. Symons, J.D., Abel, E.D., Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide. Rev Endocr Metab Disord 14 (2013), 59–68.
39. Sarma, S., Carrick-Ranson, G., Fujimoto, N., et al. Effects of age and aerobic fitness on myocardial lipid content. Circ Cardiovasc Imaging 6 (2013), 1048–1055.
40. Lindman, B.R., Dávila-Román, V.G., Mann, D.L., et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol 64 (2014), 541–549.
41. Kristensen, S.L., Mogensen, U.M., Jhund, P.S., et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction. A report from the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial (I-Preserve). Circulation 135 (2017), 724–735.
42. Mohammed, S.F., Borlaug, B.A., Roger, V.L., et al. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community based study. Circ Heart Fail 5 (2012), 710–719.
43. MacDonald, M.R., She, L., Doenst, T., et al. Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. Eur J Heart Fail 17 (2015), 725–734.
44. Shah, A.M., Shin, S.H., Takeuchi, M., et al. Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. Eur J Heart Fail 14 (2012), 185–192.
45. Egstrup, M., Kistorp, C.N., Schou, M., et al. Abnormal glucose metabolism is associated with reduced left ventricular contractile reserve and exercise intolerance in patients with chronic heart failure. Eur Heart J Cardiovasc Imaging 14 (2013), 349–357.
46. Höke, U., Thijssen, J., van Bommel, R.J., et al. Influence of diabetes on left ventricular systolic and diastolic function and on long-term outcome after cardiac resynchronization therapy. Diabetes Care 36 (2013), 985–991.
47. Jarnert, C., Landstedt-Hallin, L., Malmberg, K., et al. A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study. Eur J Heart Fail 11 (2009), 39–47.
48. Castagno, D., Baird-Gunning, J., Jhund, P.S., et al. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J 162 (2011), 938–948.
49. van Heerebeek, L., Paulus, W.J., The dialogue between diabetes and diastole. Eur J Heart Fail 11 (2009), 3–5.
50. Kitzman, D.W., Brubaker, P., Morgan, T., et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 315 (2016), 36–46.
51. Andersson, C., Søgaard, P., Hoffmann, S., et al. Metformin is associated with improved left ventricular diastolic function measured by tissue Doppler imaging in patients with diabetes. Eur J Endocrinol 163 (2010), 593–599.
52. Lexis, C.P., van der Horst, I.C., Lipsic, E., et al. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. JAMA 311 (2014), 1526–1535.
53. Lago, R.M., Singh, P.P., Nesto, R.W., Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370 (2007), 1129–1136.
54. van der Meer, R.W., Rijzewijk, L.J., de Jong, H.W., et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 119 (2009), 2069–2077.
55. Chen, W.J., Rijzewijk, L.J., van der Meer, R.W., et al. Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men. Cardiovasc Diabetol, 10, 2011, 67.
56. Scirica, B.M., Braunwald, E., Raz, I., et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130 (2014), 1579–1588.
57. Weir, D.L., McAlister, F.A., Senthilselvan, A., Minhas-Sandhu, J.K., Eurich, D.T., Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. J Am Coll Cardiol HF 2 (2014), 573–582.
58. Scirica, B.M., The safety of dipeptidyl peptidase 4 inhibitors and the risk for heart failure. JAMA Cardiol 1 (2016), 123–125.
59. Li, L., Li, S., Deng, K., et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ, 352, 2016, i610.
60. Komajda, M., Liraglutide in heart failure: caution is needed. Eur J Heart Fail 19 (2017), 78–79.
61. Jorsal, A., Kistorp, C., Holmager, P., et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19 (2017), 69–77.
62. Fitchett, D., Zinman, B., Wanner, C., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 37 (2016), 1526–1534.
63. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
64. Sattar, N., Petrie, M.C., Zinman, B., Januzzi, J.L. Jr., Novel diabetes drugs and the cardiovascular specialist. J Am Coll Cardiol 69 (2017), 2646–2656.